NeuroSense prepares Canada new drug submission for PrimeC, targets December 2026 filing
NRSN•Canada filing plan for PrimeC
- NeuroSense began preparing a New Drug Submission to Health Canada for ALS drug PrimeC, targeting a December 2026 filing.
- Filing plan follows pre-NDS discussions, drawing on Phase 2b PARADIGM clinical and biomarker data.
